



# ichromα™ Cyfra21-1

Sensitive and specific tumor marker of non-small cell lung cancer (NSCLC)

- Quantitative fluorescence immunoassay
- Fast test result in 12 min with small sample volume
- Easier to handle and storage stable

## Cyfra21-1 test benefits

Cyfra21-1 is a sensitive and valuable biomarker for estimation of diagnosis, prognosis, and therapy monitoring of lung cancer and Boditech Med provides diverse tumor marker panel to improve the diagnostic accuracy.



## What is Cyfra21-1 test?

- Cyfra21-1 (Cytokeratin 19 fragment) belongs to a cytokeratin family, which is normally expressed throughout body fluids
- Can be used as circulating tumor marker as it is a serum-soluble antigen
- Mainly occurs in the lung, particularly in lung cancer tissues
- Can be elevated in other cancers, such as bladder, lung, breast cancers
- Although associated with small cell and NSCLC, it is most sensitive for NSCLC, primarily squamous cell carcinoma

## Clinical Usefulness

- Lung cancer is by far the leading cause of cancer death ; over than half of people with lung cancer die within one year of being diagnosed and the 5-year survival rate in advanced-stage is 15%, as compared to 80% in early-stage
- Early detection and diagnosis is urgent for the sake of an effective treatment strategy for lung cancer
- Cyfra21-1 reflects the extent of the disease and proved to be sensitive and valuable biomarkers for estimation of diagnosis, prognosis, and therapy monitoring of lung cancer


## ichroma™ Cyfra21-1 Specification

ichroma™ Cyfra21-1 is a fluorescence immunoassay (FIA) for the quantitative determination of circulating Cyfra21-1 in blood.

Test principle	Fluorescence Immunoassay (FIA)
Sample type	Serum, plasma
Sample volume	10 µL
Assay time	12 min
Reference value	3.3 ng/mL
Working range	1-500 ng/mL
Storage and shelf life	Up to 20 months at 2-30 °C
Available platform	ichroma™ II, ichroma™ III, ichroma™ M2

## Performance

ichroma™ Cyfra21-1 showed equivalent and comparable test result compared with laboratory device.



## Ordering information

Product	Cat. No.
ichroma™ Cyfra21-1	CFPC-140
ichroma™ Cyfra21-1 Control	CFPC-357
ichroma™ II	FPRR021
ichroma™ III	FPRR037
ichroma™ M2	FPRR031



## References

- 1) Gayo, Sonsoles Garcia-Valdecasas, et al. "CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value." *Advances in Laboratory Medicine/Avances en Medicina de Laboratorio* 1.4 (2020).
- 2) Wieskopf, Bram, et al. "Cyfra 21-1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role." *Chest* 108.1 (1995): 163-169.
- 3) Sokoll, Lori J., and Daniel W. Chan. "Tumor markers." *Contemporary Practice in Clinical Chemistry*. Academic Press, 2020. 779-793.
- 4) Biaoxue, Rong, et al. "Differential diagnostic CYFRA 21-1 level for benign and malignant pleural effusions: a meta-analysis in the Chinese population." *Archives of Medical Science* 8.5 (2012): 756-766.
- 5) Zhang, Li, et al. "The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients." *BMC cancer* 17.1 (2017): 1-14.
- 6) Fu, Lei, et al. "CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: a meta-analysis." *The International Journal of Biological Markers* 34.3 (2019): 251-261.
- 7) Hoseok, I., and Je-Yoel Cho. "Lung cancer biomarkers." *Advances in clinical chemistry* 72 (2015): 107-170.